Effects of curcumin, a bioactive component of turmeric, on type 2 diabetes mellitus and its complications: an updated review

Bozkurt, Osman; Kocaadam-Bozkurt, Betül; Yıldıran, Hilal

doi:10.1039/d2fo02625b

Cited by 16 publications

(16 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It modulates inflammatory pathways by inhibiting transcription factors activation such as Nuclear Factor-κB which is a potential method for the diagnosing and managing the Inflammatory CVD and reducing the interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) expression, which are pro-inflammatory cytokines [ 64 – 66 ]. By doing so, curcumin helps mitigate chronic inflammation, which is a common feature of various chronic diseases, including DM2 [ 64 , 67 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of curcumin and high-content eicosapentaenoic acid supplementations in type 2 diabetes mellitus patients: a double-blinded randomized clinical trial

Asghari,

Saleh,

Salekzamani

et al. 2024

Nutr. Diabetes

View full text Add to dashboard Cite

Background/objectives The present study investigated the effect of curcumin and eicosapentaenoic acid, as one the main components of omega-3 polyunsaturated fatty acids, on anthropometric, glucose homeostasis, and gene expression markers of cardio-metabolic risk in patients with type 2 diabetes mellitus. Subjects/methods This clinical trial was conducted at the Endocrinology Clinic of Imam Reza Hospital in Tabriz. It aimed to determine the impact of Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA), and curcumin supplements on various health indicators in patients with Type 2 Diabetes Mellitus (DM2) from 2021.02.01 to 2022.02.01. The study was a randomized double-blinded clinical trial and conducted over 12 weeks with 100 participants randomly divided into four groups. Stratified randomization was used to assign participants to two months of supplementation based on sex and Body Mass Index (BMI). The study comprised four groups: Group 1 received 2 capsules of 500 mg EPA and 200 mg DHA, along with 1 nano-curcumin placebo; Group 2 received 1 capsule of 80 mg nano-curcumin and 2 omega 3 Fatty Acids placebos; Group 3 received 2 capsules of 500 mg EPA and 200 mg DHA, and 1 capsule of 80 mg nano-curcumin; Group 4, the control, received 2 omega 3 Fatty Acids placebos and 1 nano-curcumin placebo. Results After twelve weeks of taking EPA + Nano-curcumin supplements, the patients experienced a statistically significant reduction in insulin levels in their blood [MD: −1.44 (−2.70, −0.17)]. This decrease was significantly greater than the changes observed in the placebo group [MD: −0.63 (−1.97, 0.69)]. The EPA + Nano-curcumin group also showed a significant decrease in High-Sensitivity C-Reactive Protein (hs-CRP) levels compared to the placebo group (p < 0.05). Additionally, the EPA + Nano-curcumin group had a significant increase in Total Antioxidant Capacity (TAC) levels compared to the placebo group (p < 0.01). However, there were no significant differences in Fasting Blood Sugar (FBS), Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) index, Quantitative Insulin Sensitivity Check Index (QUICKI), or Hemoglobin A1c (HbA1C) levels between the four groups (all p > 0.05). There were significant differences between the Nano-curcumin and EPA groups [MD: −17.02 (−32.99, −1.05)], and between the Nano-curcumin and control groups [MD: −20.76 (−36.73, −4.79)] in terms of lowering the serum cholesterol level. The difference in Triglycerides (TG) serum levels between the EPA + Nano-curcumin and placebo groups were not statistically significant (p = 0.093). The Nano-curcumin group showed significant decreases in Low-Density Lipoprotein (LDL) levels compared to the EPA group [MD: −20.12 (−36.90, −3.34)] and the control group [MD: −20.79 (−37.57, −4.01)]. There was a near-to-significant difference in High-Density Lipoprotein (HDL) serum levels between the EPA + Nano-curcumin and EPA groups (p = 0.056). Finally, there were significant differences in the decrease of serum Vascular Endothelial Growth Factor (VEGF) levels between the EPA and Nano-curcumin groups [MD: −127.50 (−247.91, −7.09)], the EPA and placebo groups [MD: 126.25 (5.83, 246.66)], the EPA + Nano-curcumin and Nano-curcumin groups [MD: −122.76 (−243.17, −2.35)], and the EPA + Nano- curcumin and placebo groups [MD: 121.50 (1.09, 241.92)]. Conclusions The findings of the present study suggest that 12-week supplementation with EPA and Nano-curcumin may positively impact inflammation, oxidative stress, and metabolic parameters in patients with diabetes. The supplementation of EPA and Nano-curcumin may be a potential intervention to manage diabetes and reduce the risk of complications associated with diabetes. However, further research is needed to validate the study’s findings and establish the long-term effects of EPA and Nano-curcumin supplementation in patients with diabetes.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Curcumin possesses strong antioxidant properties [ 67 ]. It scavenges free radicals and ROS, thereby reducing oxidative stress [ 64 ].…”

Section: Discussionmentioning

confidence: 99%

The effect of curcumin and high-content eicosapentaenoic acid supplementations in type 2 diabetes mellitus patients: a double-blinded randomized clinical trial

Asghari,

Saleh,

Salekzamani

et al. 2024

Nutr. Diabetes

View full text Add to dashboard Cite

show abstract

“…Previous research study reported that curcumin had affected the enzyme PTP1B by increasing the sensitivity of hepatic leptin and insulin of rat liver [14,15]. Curcumin also inhibited PTP1B enzyme action that leads to improve hepatic leptin and insulin signaling in rats fed with fructose [16][17][18][19][20]. In addition, curcumin remarkably reduced the podocyte injury and proteinuria induced by fructose, the expression of PTP1B, and cut down the activity of insulin receptor and insulin receptor substrate 1 of fructose-fed rats [21].…”

Section: Introductionmentioning

confidence: 98%

Curcumins from <em>Curcuma longa </em>Potential Inhibit PTP1B and α-Glucosidase: Experimental and Computational Study

Dinh¹,

Nguyen²,

Quan³

et al. 2023

Preprint

View full text Add to dashboard Cite

Curcuma longa is only a rich source of curcumin (1) and its major analogues demethoxycurcumin (2) and bisdemethoxycurcumin (3) among the Curcuma species. The content ratio of these three curcumins in turmeric is depended on the varieties and growing environment. Recently, curcumin (1) has been reported as potential inhibitor of hepatic and enzymatic protein tyrosine phosphatase 1B (PTP1B) and its related disorders such as hypertriglyceridemia, hyperlipidemia and liver steatosis. Thus, we further purified curcumins (1–3) from C. longa and investigated their inhibitory effects against PTP1B and α-glucosidase enzymes. As the result, curcumins (1–3) exhibited potential PTP1B inhibition with IC50 values of 37.8 ± 1.4, 45.3 ± 0.7, and 72.6 ± 1.1 μM, respectively, and α-glucosidase inhibition with similar manner (IC50 values of 78.2 ± 0.2, 82.4 ± 0.6, and 90.6 ± 1.0 μM, respectively). These results reveal a key role of methoxylation in the variation of PTP1B and α-glucosidase inhibitory activity for these curcumins. In addition, density functional theory (DFT) was used accompanying with molecular docking (MD) to analyze the ligand stability and the interaction of curcumins (1–3) with PTP1B and glucoside hydrolase proteins. Assay-based results and the MD data obtained are highly correlation suggesting that the deterioration of the enzyme activity caused by the distortion of structural conformation of PTP1B and glucoside hydrolase may be related to the arrangement of amino acids in protein structure. This reported for the first time that inhibitory effects of curcumins (1–3) against PTP1B and glucoside hydrolase have been examined in vitro and in silico as well.

show abstract

“…CUR is a natural yellow pigment that has attracted much attention in recent years owing to its wide spectrum of biological properties, including antioxidant, anti-inflammatory, anti-tumour, and anti-microbial activities [ 20 , 21 ]. CUR improved cardiovascular structure and function, especially with the normalisation of systolic blood pressure (SBP) and collagen deposition in rats with diet-induced metabolic syndrome [ 22 ].…”

Section: Introductionmentioning

confidence: 99%

The Combined Treatment of Curcumin with Verapamil Ameliorates the Cardiovascular Pathology in a Williams–Beuren Syndrome Mouse Model

Abdalla

Ortiz‐Romero

Rodriguez-Rovira

et al. 2023

IJMS

View full text Add to dashboard Cite

Williams–Beuren syndrome (WBS) is a rare disorder caused by a recurrent microdeletion with hallmarks of cardiovascular manifestations, mainly supra-valvular aortic stenosis (SVAS). Unfortunately, there is currently no efficient treatment. We investigated the effect of chronic oral treatment with curcumin and verapamil on the cardiovascular phenotype of a murine model of WBS harbouring a similar deletion, CD (complete deletion) mice. We analysed systolic blood pressure in vivo and the histopathology of the ascending aorta and the left ventricular myocardium to determine the effects of treatments and their underlying mechanism. Molecular analysis showed significantly upregulated xanthine oxidoreductase (XOR) expression in the aorta and left ventricular myocardium of CD mice. This overexpression is concomitant with increased levels of nitrated proteins as a result of byproduct-mediated oxidative stress damage, indicating that XOR-generated oxidative stress impacts the pathophysiology of cardiovascular manifestations in WBS. Only the combined therapy of curcumin and verapamil resulted in a significant improvement of cardiovascular parameters via activation of the nuclear factor erythroid 2 (NRF2) and reduction of XOR and nitrated protein levels. Our data suggested that the inhibition of XOR and oxidative stress damage could help prevent the severe cardiovascular injuries of this disorder.

show abstract

Effects of curcumin, a bioactive component of turmeric, on type 2 diabetes mellitus and its complications: an updated review

Abstract: Type 2 Diabetes Mellitus (T2DM) is a substantial issue in public health. Recently, there has been considerable interest in the effectiveness of using herbal supplements in T2DM. Among the herbal...

Cited by 16 publications

References 81 publications

The effect of curcumin and high-content eicosapentaenoic acid supplementations in type 2 diabetes mellitus patients: a double-blinded randomized clinical trial

The effect of curcumin and high-content eicosapentaenoic acid supplementations in type 2 diabetes mellitus patients: a double-blinded randomized clinical trial

Curcumins from <em>Curcuma longa </em>Potential Inhibit PTP1B and α-Glucosidase: Experimental and Computational Study

The Combined Treatment of Curcumin with Verapamil Ameliorates the Cardiovascular Pathology in a Williams–Beuren Syndrome Mouse Model

Contact Info

Product

Resources

About